CUSIP 55287L101 · who reports it, how much, and how much it matters to them
23 of the 720 hedge fund managers we track reported shares of MBX Biosciences, Inc. (Nasdaq: MBX) on Form 13F for 30 June 2026. Between them they reported USD 619m. The largest position belongs to Orbimed Advisors, at USD 189m.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Orbimed Advisors1 fund on PPLI.com | USD 189m | 3.5% |
| 2 | Deep Track Capital1 fund on PPLI.com | USD 96m | 1.4% |
| 3 | Polar Capital LLP26 funds on PPLI.com | USD 89m | 0.2% |
| 4 | Kynam Capital Management1 fund on PPLI.com | USD 52m | 2.9% |
| 5 | Braidwell12 funds on PPLI.com | USD 39m | 1.5% |
| 6 | Cormorant Asset Management1 fund on PPLI.com | USD 30m | 1.6% |
| 7 | Marshall Wace LLP84 funds on PPLI.com | USD 22m | 0.0% |
| 8 | ECOR1 Capital3 funds on PPLI.com | USD 21m | 1.0% |
| 9 | Rock Springs Capital Management2 funds on PPLI.com | USD 16m | 0.8% |
| 10 | Schonfeld Strategic Advisors30 funds on PPLI.com | USD 14m | 0.0% |
| 11 | Millennium Management6 funds on PPLI.com | USD 12m | 0.0% |
| 12 | D. E. Shaw & Co.15 funds on PPLI.com | USD 10m | 0.0% |
| 13 | Two Sigma Investments35 funds on PPLI.com | USD 6.3m | 0.0% |
| 14 | Burkehill Global Management5 funds on PPLI.com | USD 5.5m | 0.2% |
| 15 | PFM Health Sciences3 funds on PPLI.com | USD 3.9m | 0.3% |
| 16 | Boothbay Fund Management2 funds on PPLI.com | USD 3.9m | 0.1% |
| 17 | Moore Capital Management7 funds on PPLI.com | USD 3.6m | 0.1% |
| 18 | Platinum Investment Management11 funds on PPLI.com | USD 2.4m | 0.6% |
| 19 | Dafna Capital Management6 funds on PPLI.com | USD 652,000 | 0.1% |
| 20 | HighVista Strategies27 funds on PPLI.com | USD 642,000 | 0.1% |
| 21 | Brevan Howard Capital Management39 funds on PPLI.com | USD 475,000 | 0.0% |
| 22 | Verdad Advisers6 funds on PPLI.com | USD 252,000 | 0.2% |
| 23 | The Quarry1 fund on PPLI.com | USD 994 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Orbimed Advisors | USD 189m | 3.5% |
| 2 | Kynam Capital Management | USD 52m | 2.9% |
| 3 | Cormorant Asset Management | USD 30m | 1.6% |
| 4 | Braidwell | USD 39m | 1.5% |
| 5 | Deep Track Capital | USD 96m | 1.4% |
| 6 | ECOR1 Capital | USD 21m | 1.0% |
| 7 | Rock Springs Capital Management | USD 16m | 0.8% |
| 8 | Platinum Investment Management | USD 2.4m | 0.6% |
| 9 | PFM Health Sciences | USD 3.9m | 0.3% |
| 10 | Verdad Advisers | USD 252,000 | 0.2% |
MBX Biosciences, Inc. trades under the symbol MBX on the Nasdaq. Its CUSIP, the code used on Form 13F, is 55287L101.
23 of the 720 hedge fund managers PPLI.com tracks reported MBX Biosciences, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Orbimed Advisors (USD 189m), Deep Track Capital (USD 96m), Polar Capital LLP (USD 89m), Kynam Capital Management (USD 52m) and Braidwell (USD 39m).
23 managers in our coverage reported it, and between them they run 324 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Orbimed Advisors, where the position was 3.5% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with MBX Biosciences, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.